Literature DB >> 31484991

Ruxolitinib is an effective steroid sparing agent in bronchiolitis obliterans due to chronic graft-versus-host-disease.

Christopher Streiler1, Faizan Shaikh2, Christian Davis3, Sunil Abhyankar4, Kyle R Brownback2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31484991     DOI： 10.1038/s41409-019-0662-6

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  5 in total

1.  Ruxolitinib as an Effective and Steroid-Sparing First-Line Treatment in Newly Diagnosed BOS Patients After Hematopoietic Stem Cell Transplantation.

Authors:  Xiaoyu Zhang; Xiaoli Zhao; Yuyan Shen; Yuanyuan Shi; Lining Zhang; Mengze Hao; Fei Zhao; Rongli Zhang; Jialin Wei; Sizhou Feng; Yi He; Erlie Jiang; Mingzhe Han
Journal:  Front Pharmacol       Date:  2022-07-05       Impact factor: 5.988

2.  Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary.

Authors:  Robert F Tamburro; Kenneth R Cooke; Stella M Davies; Samuel Goldfarb; James S Hagood; Ashok Srinivasan; Marie E Steiner; Dennis Stokes; Nancy DiFronzo; Nahed El-Kassar; Nonniekaye Shelburne; Aruna Natarajan
Journal:  Ann Am Thorac Soc       Date:  2021-03

3.  Ruxolitinib treatment for bronchiolitis obliterans syndrome following hematopoietic stem cell transplant in a patient with primary hemophagocytic lymphohistiocytosis.

Authors:  Guang-Qiang Meng; Yi-Ni Wang; Jing-Shi Wang; Zhao Wang
Journal:  Chin Med J (Engl)       Date:  2021-01-05       Impact factor: 2.628

Review 4.  Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions.

Authors:  Allan R Glanville; Christian Benden; Anne Bergeron; Guang-Shing Cheng; Jens Gottlieb; Erika D Lease; Michael Perch; Jamie L Todd; Kirsten M Williams; Geert M Verleden
Journal:  ERJ Open Res       Date:  2022-07-25

5.  Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.

Authors:  Dong Wang; Yin Liu; Xiaoxuan Lai; Jia Chen; Qiao Cheng; Xiao Ma; Zhihong Lin; Depei Wu; Yang Xu
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.